Biotech company developing next-generation antibiotics against multi-drug resistant bacteria. The company is advancing a complementary pipeline of small molecules against novel bacterial targets and with innovative modes of action to prevent resistance. Its lead program is an inhibitor of lipopolysaccharide synthesis in Gram-negative bacteria, and it also develops activators that trigger bacterial self-digestion.